Pavan K Bendapudi 1 , Shelley Hurwitz 2 , Ashley Fry 3 , Marisa B Marques 4 , Stephen W Waldo 5 , Ang Li 6 , Lova Sun 6 , Vivek Upadhyay 6 , Ayad Hamdan 7 , Andrew M Brunner 8 , John M Gansner 9 , Srinivas Viswanathan 8 , Richard M Kaufman 10 , Lynne Uhl 11 , Christopher P Stowell 12 , Walter H Dzik 13 , Robert S Makar 12
Mar 01 2017
Among the syndromes characterised by thrombotic microangiopathy, thrombotic thrombocytopenic purpura is distinguished by a severe deficiency in the ADAMTS13 enzyme. Patients with this disorder need urgent treatment with plasma exchange. Because ADAMTS13 activity testing typically requires prolonged turnaround times and might be unavailable in resource-poor settings, a method to rapidly assess the likelihood of severe ADAMTS13 deficiency is needed.